CA1341423C
(en)
*
|
1984-10-31 |
2003-03-04 |
Paul A. Luciw |
Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
|
US5008182A
(en)
*
|
1986-01-10 |
1991-04-16 |
Cetus Corporation |
Detection of AIDS associated virus by polymerase chain reaction
|
JPS63501923A
(ja)
*
|
1985-12-05 |
1988-08-04 |
フレツド ハツチンソン キヤンサ− リサ−チ センタ− |
レトロウイルス疾病状態の治療のためのアンチセンスrna
|
US5637573A
(en)
*
|
1986-05-23 |
1997-06-10 |
Agrawal; Sudhir |
Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions
|
US5268268A
(en)
*
|
1986-11-26 |
1993-12-07 |
Hoffmann-La Roche Inc. |
Detection of HTLVI and HTLVII viruses by hybridization
|
US5079351A
(en)
*
|
1986-11-26 |
1992-01-07 |
Cetus Corporation |
Oligonucleotides and kits for detection of htlvi and htlvii viruses by hybridization
|
US5110802A
(en)
*
|
1987-07-14 |
1992-05-05 |
City Of Hope |
Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
|
DE3855864T2
(de)
|
1987-11-30 |
1997-09-25 |
Univ Iowa Res Found |
Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
|
US5104791A
(en)
*
|
1988-02-09 |
1992-04-14 |
E. I. Du Pont De Nemours And Company |
Particle counting nucleic acid hybridization assays
|
DE68929343T2
(de)
*
|
1988-02-16 |
2002-09-12 |
Greatbatch Gen Aid Ltd |
Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
|
US5580761A
(en)
*
|
1988-02-16 |
1996-12-03 |
Greatbatch Gen-Aid Ltd. |
Method of conferring resistance to immunodeficiency viral infection
|
EP0402402B1
(de)
*
|
1988-02-26 |
1995-12-27 |
Worcester Foundation For Biomedical Research, Inc. |
Hemmung von htlv-iii durch exogene oligonukleotide
|
US5278302A
(en)
*
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
US5602244A
(en)
*
|
1988-05-26 |
1997-02-11 |
Competitive Technologies, Inc. |
Polynucleotide phosphorodithioate compounds
|
US5750666A
(en)
*
|
1988-05-26 |
1998-05-12 |
Competitve Technologies, Inc. |
Polynucleotide phosphorodithioate compounds
|
ATE137806T1
(de)
*
|
1988-07-05 |
1996-05-15 |
Baylor College Medicine |
Verfahren zur identifizierung von bakterien
|
GB8827592D0
(en)
*
|
1988-11-25 |
1988-12-29 |
Taniguchi T |
Improvements in & relating to regulation of expression
|
US5176996A
(en)
*
|
1988-12-20 |
1993-01-05 |
Baylor College Of Medicine |
Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
|
US5734033A
(en)
*
|
1988-12-22 |
1998-03-31 |
The Trustees Of The University Of Pennsylvania |
Antisense oligonucleotides inhibiting human bcl-2 gene expression
|
US6841541B1
(en)
|
1992-02-21 |
2005-01-11 |
The Trustees Of The University Of Pennsylvania |
Regulation of BCL-2-gene expression
|
US5831066A
(en)
|
1988-12-22 |
1998-11-03 |
The Trustees Of The University Of Pennsylvania |
Regulation of bcl-2 gene expression
|
WO1990011092A1
(en)
*
|
1989-03-21 |
1990-10-04 |
Vical, Inc. |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US6673776B1
(en)
|
1989-03-21 |
2004-01-06 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
|
US6867195B1
(en)
*
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
US5703055A
(en)
*
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US5693622A
(en)
*
|
1989-03-21 |
1997-12-02 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
|
US6214804B1
(en)
|
1989-03-21 |
2001-04-10 |
Vical Incorporated |
Induction of a protective immune response in a mammal by injecting a DNA sequence
|
ZA902912B
(en)
*
|
1989-04-21 |
1991-01-30 |
Cornell Res Foundation Inc |
Method of inhibiting induction of latent or chronic viral infection
|
US5871958A
(en)
*
|
1989-05-25 |
1999-02-16 |
Duke University |
Mutant rev genes encoding transdominant repressors of HIV replication
|
US6251675B1
(en)
|
1989-05-25 |
2001-06-26 |
Duke University |
Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication
|
ES2275451T3
(es)
*
|
1989-06-02 |
2009-02-16 |
Institut Pasteur |
Secuencias nucleotidicas procedentes del genoma de los retrovirus del tipo vih-1,vih-2 y siv, y sus aplicaciones especialmente para la amplificacion de los genomas de estos retrovirus y para el diagnostico in vitro de las infecciones debidas a estos virus.
|
US7022814B1
(en)
|
1992-01-21 |
2006-04-04 |
Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale |
Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
|
FR2647810B1
(fr)
*
|
1989-06-02 |
1994-07-22 |
Pasteur Institut |
Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
|
FR2647809B1
(fr)
*
|
1989-06-02 |
1991-09-20 |
Pasteur Institut |
Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
|
WO1990015814A1
(en)
*
|
1989-06-20 |
1990-12-27 |
Meiogenics, Inc. |
Nuclease resistant, single-stranded, non-naturally occurring nucleic acid molecules
|
US5580722A
(en)
*
|
1989-07-18 |
1996-12-03 |
Oncogene Science, Inc. |
Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
|
US6203976B1
(en)
*
|
1989-07-18 |
2001-03-20 |
Osi Pharmaceuticals, Inc. |
Methods of preparing compositions comprising chemicals capable of transcriptional modulation
|
EP0483249B1
(de)
*
|
1989-07-18 |
2003-04-23 |
OSI Pharmaceuticals, Inc. |
Methode der veränderung der expression von genen bei der transkription und zum nachweis von chemischen substanzen, die wie modulatoren der genexpression wirken
|
US5776502A
(en)
|
1989-07-18 |
1998-07-07 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating gene expression
|
US5665543A
(en)
*
|
1989-07-18 |
1997-09-09 |
Oncogene Science, Inc. |
Method of discovering chemicals capable of functioning as gene expression modulators
|
WO1991003260A1
(en)
*
|
1989-09-01 |
1991-03-21 |
Temple University Of The Commonwealth System Of Higher Education |
Antisense oligonucleotides to c-abl proto-oncogene
|
WO1991007487A1
(en)
*
|
1989-11-16 |
1991-05-30 |
Duke University |
Particle-mediated transformation of animal tissue cells
|
WO1991008313A1
(en)
*
|
1989-12-04 |
1991-06-13 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of papillomavirus
|
US5959096A
(en)
*
|
1992-03-16 |
1999-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US6753423B1
(en)
|
1990-01-11 |
2004-06-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US6339066B1
(en)
|
1990-01-11 |
2002-01-15 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
|
US20040142899A1
(en)
*
|
1990-01-11 |
2004-07-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US5248670A
(en)
*
|
1990-02-26 |
1993-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides for inhibiting herpesviruses
|
US6228844B1
(en)
|
1991-11-12 |
2001-05-08 |
Vical Incorporated |
Stimulating vascular growth by administration of DNA sequences encoding VEGF
|
US20030186913A1
(en)
*
|
1990-03-21 |
2003-10-02 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US6706694B1
(en)
|
1990-03-21 |
2004-03-16 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate
|
AU7759291A
(en)
*
|
1990-03-29 |
1991-10-21 |
Gilead Sciences, Inc. |
Oligonucleotide-transport agent disulfide conjugates
|
WO1991015226A1
(en)
*
|
1990-04-09 |
1991-10-17 |
The American National Red Cross |
Rejuvenation compositions and methods for their use
|
US5610050A
(en)
*
|
1990-04-20 |
1997-03-11 |
The General Hospital Corporation |
Methods of preventing viral replication
|
KR970004802B1
(ko)
*
|
1990-04-30 |
1997-04-04 |
아이시스 파마슈티칼스, 인코포레이티드 |
올리고뉴클레오티드를 이용한 아라키돈산 대사조절
|
EP0529008B1
(de)
*
|
1990-05-04 |
1999-12-15 |
Isis Pharmaceuticals, Inc. |
Modulation der genexpression durch eingreifen in die rna sekundärstruktur
|
US6034233A
(en)
*
|
1990-05-04 |
2000-03-07 |
Isis Pharmaceuticals Inc. |
2'-O-alkylated oligoribonucleotides and phosphorothioate analogs complementary to portions of the HIV genome
|
US5166195A
(en)
*
|
1990-05-11 |
1992-11-24 |
Isis Pharmaceuticals, Inc. |
Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
|
BR9106486A
(pt)
*
|
1990-05-23 |
1993-05-25 |
Isis Pharmaceuticals Inc |
Composicao para modulacao da atividade de um rna e processo para tratamento de um organismo que tem uma doenca que se caracteriza para producao indesejada de uma proteina
|
WO1992005284A1
(en)
*
|
1990-09-21 |
1992-04-02 |
University Of Maryland |
Compositions and methods for inhibiting growth or replication of viruses
|
AU1258292A
(en)
*
|
1991-01-18 |
1992-08-27 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating expression of hematopoietic growth factor genes
|
WO1992013063A1
(en)
*
|
1991-01-18 |
1992-08-06 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes
|
WO1992013091A1
(en)
*
|
1991-01-18 |
1992-08-06 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
|
AU1347292A
(en)
*
|
1991-01-18 |
1992-08-27 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating gene expression of viral genes and other genes
|
WO1992021690A1
(en)
*
|
1991-06-05 |
1992-12-10 |
Triplex Pharmaceutical Corporation |
Purine base modified 2'-deoxyribonucleosides, use in triplex forming oligonucleotides and process for preparing the same
|
EP0558697A1
(de)
*
|
1991-06-28 |
1993-09-08 |
Massachusetts Institute Of Technology |
Lokale oligonukleotiden Behandlung
|
US5646267A
(en)
*
|
1991-08-05 |
1997-07-08 |
Polish Academy Of Sciences |
Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
|
US5359052A
(en)
*
|
1991-08-05 |
1994-10-25 |
Polish Academy Of Sciences |
Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
|
US7119184B2
(en)
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US6369209B1
(en)
|
1999-05-03 |
2002-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
WO1993006122A1
(en)
*
|
1991-09-27 |
1993-04-01 |
Allelix Biopharmaceuticals Inc. |
Duplex-forming, polynucleotide conjugates
|
DE59208572D1
(de)
*
|
1991-10-17 |
1997-07-10 |
Ciba Geigy Ag |
Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
NZ244820A
(en)
*
|
1991-10-25 |
1994-01-26 |
Isis Pharmaceuticals Inc |
Oligonucleotide inhibitor of epstein-barr virus.
|
CA2122473C
(en)
|
1991-10-31 |
2001-01-23 |
Lee Anne Beausang |
Nuclear matrix protein fluid assay
|
AU3129993A
(en)
*
|
1991-11-08 |
1993-06-07 |
Massachusetts Institute Of Technology |
Localized oligonucleotide therapy
|
US5332814A
(en)
*
|
1991-11-12 |
1994-07-26 |
Ciba-Geigy Corporation |
Process for the preparation of carbacyclic nucleosides, and intermediates
|
US5274157A
(en)
*
|
1991-11-12 |
1993-12-28 |
Ciba-Geigy Corporation |
Protected formylpentanediols, hydroxymethylpentanediols, process for their preparation and intermediates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
CA2126451A1
(en)
|
1991-12-24 |
1993-07-08 |
Brett P. Monia |
Compositions and methods for modulating .beta.-amyloid
|
EP0619736A1
(de)
*
|
1991-12-31 |
1994-10-19 |
Worcester Foundation For Biomedical Research, Inc. |
Antiparasitäre Oligonucleotide mit einer Wirkung gegen arzneimittelrestistenteMalaria
|
US5885970A
(en)
*
|
1992-03-16 |
1999-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US5681747A
(en)
*
|
1992-03-16 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
|
US5916807A
(en)
*
|
1992-03-16 |
1999-06-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US6153599A
(en)
*
|
1992-03-16 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
|
US6537973B1
(en)
|
1992-03-16 |
2003-03-25 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide inhibition of protein kinase C
|
US6117847A
(en)
*
|
1992-03-16 |
2000-09-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for enhanced modulation of protein kinase C expression
|
US5922686A
(en)
*
|
1992-03-16 |
1999-07-13 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of protein kinase C
|
US5882927A
(en)
*
|
1992-03-16 |
1999-03-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide inhibition of protein kinase C
|
US5643780A
(en)
*
|
1992-04-03 |
1997-07-01 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
|
US5411860A
(en)
*
|
1992-04-07 |
1995-05-02 |
The Johns Hopkins University |
Amplification of human MDM2 gene in human tumors
|
EP0647270B1
(de)
*
|
1992-06-22 |
2004-01-07 |
Matritech, Inc. |
Neuartige marker maligner zelltypen in der inneren nukleären matrix
|
EP0577558A2
(de)
*
|
1992-07-01 |
1994-01-05 |
Ciba-Geigy Ag |
Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
|
AU4674393A
(en)
*
|
1992-07-20 |
1994-02-14 |
Isis Pharmaceuticals, Inc. |
Pseudo-half-knot rna formation by hybridization of antisense oligonucleotides to target rna's secondary structure
|
TW244371B
(de)
*
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
US6346614B1
(en)
*
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
US6995146B2
(en)
|
1992-09-10 |
2006-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US6423489B1
(en)
|
1992-09-10 |
2002-07-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
US6391542B1
(en)
|
1992-09-10 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
US6174868B1
(en)
|
1992-09-10 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US20040049021A1
(en)
*
|
1992-09-10 |
2004-03-11 |
Anderson Kevin P. |
Compositions and mehtods for treatment of Hepatitis C virus-associated diseases
|
WO1994005813A1
(en)
*
|
1992-09-10 |
1994-03-17 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
Compositions and methods for treatment of hepatitis c virus-associated diseases
|
US5985558A
(en)
*
|
1997-04-14 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
|
US5593972A
(en)
*
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
ATE302854T1
(de)
*
|
1993-01-26 |
2005-09-15 |
Univ Pennsylvania |
Zusammensetzungen und verfahren zur verabreichung von genetischem material
|
US7001759B1
(en)
|
1993-01-26 |
2006-02-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for delivery of genetic material
|
US5981505A
(en)
*
|
1993-01-26 |
1999-11-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for delivery of genetic material
|
US20040087521A1
(en)
*
|
1993-03-18 |
2004-05-06 |
Merck & Co., Inc. |
Nucleic acid pharmaceuticals-influenza matrix
|
EP0626387B1
(de)
*
|
1993-05-12 |
1999-03-10 |
Novartis AG |
Nukleoside und Oligonukleotide mit 2'-Ethergruppen
|
WO1994027435A1
(en)
|
1993-06-01 |
1994-12-08 |
Life Technologies, Inc. |
Genetic immunization with cationic lipids
|
CA2166889C
(en)
*
|
1993-07-19 |
2001-09-11 |
Todd C. Peterson |
Oligonucleotides with activity against human immunodeficiency virus
|
US5739309A
(en)
*
|
1993-07-19 |
1998-04-14 |
Gen-Probe Incorporated |
Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
|
US5571902A
(en)
*
|
1993-07-29 |
1996-11-05 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides
|
US6001982A
(en)
*
|
1993-07-29 |
1999-12-14 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides
|
US6294664B1
(en)
|
1993-07-29 |
2001-09-25 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides
|
ATE247128T1
(de)
|
1993-09-03 |
2003-08-15 |
Isis Pharmaceuticals Inc |
Aminoderivatisierte nukleoside und oligonukleoside
|
US6348449B1
(en)
*
|
1993-09-21 |
2002-02-19 |
The Trustees Of The University Of Pennsylvania |
Methods of inducing mucosal immunity
|
US5510239A
(en)
*
|
1993-10-18 |
1996-04-23 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of multidrug resistance-associated protein
|
US5807838A
(en)
*
|
1994-09-23 |
1998-09-15 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of multidrug resistance-associated protein
|
DE4338704A1
(de)
*
|
1993-11-12 |
1995-05-18 |
Hoechst Ag |
Stabilisierte Oligonucleotide und deren Verwendung
|
HU220423B
(hu)
*
|
1994-01-26 |
2002-01-28 |
Novartis Ag. |
Módosított oligonukleotidok
|
US6995008B1
(en)
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
DE59510742D1
(de)
*
|
1994-04-27 |
2003-08-14 |
Novartis Ag |
Nukleoside und Oligonukleotide mit 2'-Ethergruppen
|
US6090626A
(en)
*
|
1994-05-31 |
2000-07-18 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US5563255A
(en)
*
|
1994-05-31 |
1996-10-08 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US20060142236A1
(en)
*
|
1994-05-31 |
2006-06-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US6410518B1
(en)
|
1994-05-31 |
2002-06-25 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
US20030119769A1
(en)
*
|
1994-05-31 |
2003-06-26 |
Monia Brett P |
Antisense oligonucleotide modulation of raf gene expression
|
US5656612A
(en)
*
|
1994-05-31 |
1997-08-12 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US6358932B1
(en)
|
1994-05-31 |
2002-03-19 |
Isis Pharmaceticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
US5744362A
(en)
*
|
1994-05-31 |
1998-04-28 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
KR100211178B1
(ko)
*
|
1994-05-31 |
1999-07-15 |
파샬 비. 린네 |
라프유전자 발현의 안티센스 올리고뉴클레오티드 조절
|
US5691316A
(en)
*
|
1994-06-01 |
1997-11-25 |
Hybridon, Inc. |
Cyclodextrin cellular delivery system for oligonucleotides
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US5733781A
(en)
|
1994-07-19 |
1998-03-31 |
Gen-Probe Incorporated |
Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
|
DE4427219A1
(de)
*
|
1994-08-01 |
1996-02-08 |
Max Planck Gesellschaft |
Nukleinsäure zur Initiation der Aktivität von RNase H bzw. reverser Transkriptase
|
JPH10504819A
(ja)
*
|
1994-08-10 |
1998-05-12 |
オルトマン、シドニー |
アンチセンスおよびトリプレックス治療薬および方法
|
WO1996007668A1
(de)
*
|
1994-09-02 |
1996-03-14 |
Novartis Ag |
Funktionelle terpyridin-metallkomplexe, verfahren zu deren herstellung und oligonukleotid-konjugate mit terpyridin-metallkomplexen
|
ATE340866T1
(de)
*
|
1994-10-28 |
2006-10-15 |
Gen Probe Inc |
Zusammensetzungen und verfahren für die gleichzeitige detektion und quantifizierung von einer mehrheit spezifischer nuklein säure sequenzen
|
CA2212682A1
(en)
|
1995-02-10 |
1996-08-15 |
Worcester Foundation For Experimental Biology, Inc. |
Delivery of exogenous compounds
|
US6117993A
(en)
*
|
1995-05-23 |
2000-09-12 |
Hybridon, Inc. |
Synthons for oligonucleotide synthesis
|
US5750674A
(en)
*
|
1995-05-23 |
1998-05-12 |
Hybridon, Inc. |
Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced
|
US5693773A
(en)
*
|
1995-06-07 |
1997-12-02 |
Hybridon Incorporated |
Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
|
US5985662A
(en)
*
|
1995-07-13 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of hepatitis B virus replication
|
US6624293B1
(en)
|
1995-08-17 |
2003-09-23 |
Hybridon, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
US5652356A
(en)
*
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
US7074768B2
(en)
|
1995-08-17 |
2006-07-11 |
Idera Pharmaceuticals, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
US5981180A
(en)
*
|
1995-10-11 |
1999-11-09 |
Luminex Corporation |
Multiplexed analysis of clinical specimens apparatus and methods
|
GB9604669D0
(en)
|
1996-03-05 |
1996-05-01 |
Ciba Geigy Ag |
Chemical compounds
|
CA2250923A1
(en)
*
|
1996-03-26 |
1997-10-02 |
Gabriella Zupi |
Oligonucleotide treatments and compositions for human melanoma
|
US5856099A
(en)
*
|
1996-05-21 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Antisense compositions and methods for modulating type I interleukin-1 receptor expression
|
US6776986B1
(en)
|
1996-06-06 |
2004-08-17 |
Novartis Ag |
Inhibition of HIV-1 replication by antisense RNA expression
|
WO1998003646A1
(en)
*
|
1996-07-22 |
1998-01-29 |
Hybridon, Inc. |
Compositions and methods for treating specific gene expression-related diseases and disorders in humans
|
US5856462A
(en)
*
|
1996-09-10 |
1999-01-05 |
Hybridon Incorporated |
Oligonucleotides having modified CpG dinucleosides
|
US5885834A
(en)
*
|
1996-09-30 |
1999-03-23 |
Epstein; Paul M. |
Antisense oligodeoxynucleotide against phosphodiesterase
|
US6001991A
(en)
*
|
1996-10-04 |
1999-12-14 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
|
US6449562B1
(en)
|
1996-10-10 |
2002-09-10 |
Luminex Corporation |
Multiplexed analysis of clinical specimens apparatus and method
|
US7235653B2
(en)
*
|
1996-12-31 |
2007-06-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6319906B1
(en)
|
1996-12-31 |
2001-11-20 |
Isis Pharmaceuticals |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US20040023917A1
(en)
*
|
1996-12-31 |
2004-02-05 |
Bennett C. Frank |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6077833A
(en)
*
|
1996-12-31 |
2000-06-20 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
WO1998042722A1
(en)
|
1997-03-21 |
1998-10-01 |
President And Fellows Of Harvard College |
Antisense inhibition of angiogenin expression
|
US6887906B1
(en)
|
1997-07-01 |
2005-05-03 |
Isispharmaceuticals, Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
US5877309A
(en)
*
|
1997-08-13 |
1999-03-02 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against JNK
|
US6809193B2
(en)
|
1997-08-13 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US6133246A
(en)
*
|
1997-08-13 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US20070149472A1
(en)
*
|
1997-08-13 |
2007-06-28 |
Mckay Robert |
Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
|
ATE317432T1
(de)
*
|
1997-08-19 |
2006-02-15 |
Idera Pharmaceuticals Inc |
Hiv-spezifische oligonukleotide und verfahren zu deren verwendung
|
US20030036516A1
(en)
*
|
1997-09-10 |
2003-02-20 |
Sudhir Agrawal |
Method for using oligonucleotides having modified cpg dinucleotides
|
US6306831B1
(en)
|
1997-09-12 |
2001-10-23 |
Qik Technologies, Inc. |
Transplacental delivery of oligonucleotides
|
US7321828B2
(en)
*
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
US20040186071A1
(en)
*
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
JP2002515514A
(ja)
|
1998-05-21 |
2002-05-28 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドの局所送逹のための組成物及び方法
|
EP1469009A2
(de)
*
|
1998-05-21 |
2004-10-20 |
Isis Parmaceuticals, Inc. |
Zusammensetzungen und Verfahren für nicht-parenterale Verabreichung von Oligonukleotiden
|
SI1077722T1
(sl)
|
1998-05-22 |
2007-02-28 |
Ottawa Health Research Inst |
Metode in produkti za induciranje sluznicne imunosti
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
US6277967B1
(en)
|
1998-07-14 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6015676A
(en)
*
|
1998-07-31 |
2000-01-18 |
Epiclone Inc. |
Method for knocking out gene transcripts by covalently binding of an anti-sense probe
|
ES2234563T5
(es)
*
|
1999-02-12 |
2018-01-17 |
Daiichi Sankyo Company, Limited |
Nuevos análogos de nucleósidos y oligonucleótidos
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
JP4151751B2
(ja)
*
|
1999-07-22 |
2008-09-17 |
第一三共株式会社 |
新規ビシクロヌクレオシド類縁体
|
US20010011126A1
(en)
*
|
1999-09-10 |
2001-08-02 |
Bock Elisabeth Marianne |
Neurogenic compositions and methods
|
US7105962B2
(en)
*
|
2000-08-03 |
2006-09-12 |
Matsushita Electric Industrial Co., Ltd. |
Brushless motor for partable electronic equipment with wire treatment technique of coils
|
KR100917101B1
(ko)
*
|
2000-08-04 |
2009-09-15 |
도요 보세키 가부시키가이샤 |
플렉시블 금속적층체 및 그 제조방법
|
US20030096770A1
(en)
*
|
2001-07-11 |
2003-05-22 |
Krotz Achim H. |
Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
|
US8834900B2
(en)
*
|
2001-08-17 |
2014-09-16 |
University Of Iowa Research Foundation |
Combination motif immune stimulatory oligonucleotides with improved activity
|
WO2003020739A2
(en)
|
2001-09-04 |
2003-03-13 |
Exiqon A/S |
Novel lna compositions and uses thereof
|
JP2005522997A
(ja)
|
2002-02-01 |
2005-08-04 |
マクギル・ユニヴァーシティ |
交代セグメントを含むオリゴヌクレオチド及びその用途
|
US20030191075A1
(en)
*
|
2002-02-22 |
2003-10-09 |
Cook Phillip Dan |
Method of using modified oligonucleotides for hepatic delivery
|
US7569553B2
(en)
|
2002-07-03 |
2009-08-04 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7605138B2
(en)
*
|
2002-07-03 |
2009-10-20 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7807803B2
(en)
|
2002-07-03 |
2010-10-05 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US20040053880A1
(en)
*
|
2002-07-03 |
2004-03-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7576066B2
(en)
*
|
2002-07-03 |
2009-08-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US20040009483A1
(en)
*
|
2002-07-12 |
2004-01-15 |
Ilsley Diane D. |
Method of linear mRNA amplification using total RNA
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
CA2498777C
(en)
*
|
2002-09-13 |
2015-01-13 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
US20040219565A1
(en)
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
PT2241325E
(pt)
*
|
2002-10-29 |
2012-04-12 |
Coley Pharm Gmbh |
Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
|
WO2004053104A2
(en)
*
|
2002-12-11 |
2004-06-24 |
Coley Pharmaceutical Group, Inc. |
5’ cpg nucleic acids and methods of use
|
US7635560B2
(en)
*
|
2003-04-17 |
2009-12-22 |
Genesis Group Inc. |
Pygopus in diagnosis and treatment of cancer
|
DE602004023832D1
(de)
*
|
2003-05-16 |
2009-12-10 |
Univ Laval |
Cns chlorid-modulierung und verwendung derselben
|
US7960355B2
(en)
*
|
2003-05-23 |
2011-06-14 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of the expression of B7 protein
|
US7897582B2
(en)
*
|
2003-05-23 |
2011-03-01 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
CN101454451A
(zh)
*
|
2003-10-30 |
2009-06-10 |
科勒制药有限公司 |
具有增强免疫刺激能力的c类寡核苷酸类似物
|
WO2005110490A1
(en)
*
|
2004-05-14 |
2005-11-24 |
Universite Laval |
Phospholipase c gamma modulation and uses thereof for management of pain and nociception
|
EP1766015A4
(de)
*
|
2004-06-09 |
2008-10-01 |
Univ Mcgill |
Für acetylcholin-gesteuerte chloridkanal-untereinheiten aus caenorhabditis elegans codierende polynukleotide
|
MY159370A
(en)
*
|
2004-10-20 |
2016-12-30 |
Coley Pharm Group Inc |
Semi-soft-class immunostimulatory oligonucleotides
|
US20090270479A1
(en)
*
|
2005-07-12 |
2009-10-29 |
Antonio Giordano |
Genetic and Epigenetic Alterations In the Diagnosis and Treatment of Cancer
|
EP2046964B1
(de)
*
|
2006-07-12 |
2018-07-04 |
The Regents of The University of California |
Transduzierbare zuführung von nukleinsäuren durch reversible phosphotriesterladungsneutralisierungs-schutzgruppen
|
ES2641290T3
(es)
|
2007-11-20 |
2017-11-08 |
Ionis Pharmaceuticals, Inc |
Modulación de la expresión de CD40
|
US10022454B2
(en)
|
2008-09-23 |
2018-07-17 |
Liposciences, Llc |
Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis
|
EP3067359A1
(de)
|
2008-09-23 |
2016-09-14 |
Scott G. Petersen |
Selbstfreisetzende biolabile phosphatgeschützte pro-oligos für therapeutika auf oligonukleotidbasis und vermittlung von rna-interferenz
|
US20120128673A1
(en)
|
2009-05-20 |
2012-05-24 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
EP2513308B1
(de)
|
2009-12-17 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Modulation von pilr zur behandlung immunerkrankungen
|
RU2667524C2
(ru)
|
2011-04-21 |
2018-09-21 |
Ионис Фармасьютикалз, Инк. |
Модулирование экспрессии вируса гепатита b (hbv)
|
JP2015529073A
(ja)
|
2012-08-20 |
2015-10-05 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
生物可逆性基を有するポリヌクレオチド
|
CA2925500C
(en)
|
2013-09-30 |
2023-03-14 |
Geron Corporation |
Phosphorodiamidate backbone linkage for oligonucleotides
|
EP3189074B1
(de)
|
2014-09-05 |
2021-01-13 |
RSEM, Limited Partnership |
Zusammensetzungen und verfahren zur behandlung und vorbeugung von entzündungen
|
WO2019006455A1
(en)
|
2017-06-30 |
2019-01-03 |
Solstice Biologics, Ltd. |
AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
|